United Therapeutics Corporation Stock News

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q4 2020 Results - Earnings Call Transcript

United Therapeutics (UTHR) delivered earnings and revenue surprises of -26.26% and 8.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

UTHR is progressing with its next-generation dry powder formulation, Tyvaso DPI, towards the market. It plans to file an NDA under priority review in April 2021.

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study of Tyvas

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Prior

After a 63% rise since the March 23 levels of this year, at the current price of around $137 per share we believe United Therapeutics stock (NASDAQ: UTHR), a biotechnology company, has reached its nea

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FD

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and T

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q3 2020 Results - Earnings Call Transcript

Shares of United Therapeutics (NASDAQ:UTHR) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share increased 1.31% over the past year to $3.88, which beat the

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September